Executive Summary
The Medical House plc has progressively been developing a range of needle-based and needle-free devices. The ASI AutoSafety Injector is TMH's needle-based disposable autoinjector technology. In June 2005 TMH announced a development and commercialisation agreement for the ASI disposable autoinjector technology with a subsidiary of a major global healthcare products group. In January 2005, TMH announced an agreement which it has signed with Serono, to develop and license a new needle-free delivery system for the delivery of Serono's Human Growth Hormone products. In February 2005, TMH announced a 10-year agreement which it has signed with BioPartners GmbH, to supply its GH1 needle-free system for the delivery of BioPartners' Human Growth Hormone products. The market for Human Growth Hormone drugs is expected to reach $2.2 billion by 2006 according to AS Insights.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
